"MariTide delivered strong efficacy, including sustained weight loss without a plateau in the 52-week phase 2 study and meaningful improvements in cardiometabolic risk factors, representing a ...

In Cohort A, the mean percent change in weight loss from baseline to Week 52 per the treatment policy estimand 2 ranged from 12.3% to 16.2% with MariTide, compared to 2.5% with the placebo arm ...

A monthly weight loss drug from Amgen helped people lose about 20% of their body weight, according to the results of a phase 2 clinical trial. If approved, the drug, called MariTide, could make ...

Average weight loss for participants with diabetes was 17%, compared to 1.4% in the placebo group. NBC News reported that this places MariTide on par with Wegovy and Zepbound.

Amgen's (AMGN) late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls patients in its phase 3 trial.

In a statement on Monday, Amgen Inc. (NASDAQ:AMGN) announced that its phase 2 study of its weight loss drug candidate, MariTide, demonstrated up to 20 percent average weight loss in people living ...

The company said its drug, MariTide, led to significant weight loss but high rates of side effects and discontinuations in a mid-stage trial. Amgen released initial data from that trial back in ...

Also known as MariTide, maridebart cafraglutide is a long-acting peptide-antibody conjugate that combines GLP-1 receptor agonism with GIP receptor antagonism given in a single-dose auto-injection pen.

Findings from the MariTide Phase 2 Trial demonstrating weight loss and A1C reduction in groups with and without type 2 diabetes were presented as a late-breaking symposia at this year's Scientific ...